4132 results for 'part delta nr1h2'

Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f

Enhancing PD-L1 Stability: The Role of EZH2 InhibitionIn recent years, the role of PD-L1 (Programmed Death-Ligand 1) in cancer immunotherapy has garnered significant attention, particularly regarding

Parkinson's disease (PD) is a progressive neurological disorder that primarily affects the motor system, leading to a wide array of symptoms ranging from tremors and stiffness to bradykinesia (slo

Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr

Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i

A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve

BRIEF HISTORY OF THE “GREEN” EVOLUTION OF OXYGEN AND CARBON DIOXIDE WITHIN OUR ATMOSPHERE Million years ago carbon dioxide (CO2) levels used to be conside

IL-8 Overview Interleukin-8 (IL-8), also known as CXCL8, was discovered over 30 years ago as a small molecule that could promote chemotaxis and induce the production

Ovarian cancer is the fourth most common cancer in women. Ovarian cancer is when the normal cells in the ovary change and grow to form a tumour. Because the ovaries are located deep

One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping

Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.

What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W

Chemistry · Acid-BaseDeprotonation: Mechanism, pKa and Choosing the Right BaseDeprotonation is the removal of a proton from a molecule to give its conjugate base. Whether it happens, and how completel

Cell Biology · Protein DegradationThe Autophagy Pathway: Mechanism, Regulation and How to Measure ItAutophagy is the cell’s route for degrading and recycling its own contents — damaged organelles, agg

What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a

Ralitsa R. Madsen – University of Cambridge Metabolic Research Laboratories Each one of us is the result of an extraordinary developmental proces

Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun

Exploring the Role of TIM-3/Gal-9 in Antiparasitic ImmunityIntroductionThe immune system is a complex network of cells and molecules that work together to defend the body against pathogens, including